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Malignant astrocytoma of the brain remains a challenging problem, as it is rarely 
proven to be curative even with the most aggressive, comprehensive treatments. This 
makes it a good candidate for more innovative radiation therapy designed to deliver a 
higher dose to the tumor bed while minimizing the normal brain tissue radiation exposure. 
- 
Proton irradiation can offer such an advantage because the Bragg peak allows delivery of 
a higher tumor dose with good spatial resolution. This past year, the Indiana University 
School of Medicine became the 3'd active proton radiation therapy center in the United 
States, when 200-MeV protons from the Indiana University Cyclotron Facility (IUCF) 
were delivered to a patient. 
The patient is a 22-year-old Caucasian male with recently diagnosed anaplastic astro- 
cytoma located at the left occipital parietal area. The patient had a large left temporal 
anterior lobe resection 17 years ago for intractable seizure disorder. Further resection would 
be incapacitating for the patient, therefore we recommended a combination of photon and 
proton beam irradiation. The total tumor dose was 69 cobalt Gray equivalent (CGE). The 
external-beam photon treatment consisted of 54 Gy in 30 fractions to the tumor with 3 cm 
of margin using 6 MV photons. The photons were delivered through left lateral and vertex 
wedge-pair fields. The proton beam treatment consisted of 15 CGE in five fractions to the 
tumor with 1 cm of margin, with each fraction equally divided among three fields. 
Prior to treatment, three titanium screws were inserted into the patient's skull to serve 
as fiducial markers for precise patient positioning in the proton fields. After the screws 
were inserted, a spiral CT scan was performed with the patient immobilized in a specially 
designed thermoplastic mask encompassing the patient's head. The CT scans were used to 
determine the position of the tumor with respect to the titanium screws, which are clearly 
visible in the port verification films. 
Since the protons are delivered in a fixed horizontal beam line, the patient was im- 
mobilized in a seated position. A 1-cm tumor margin was given to the proton treatment 
field, which was carefully designed according to the 3-D treatment planning, with known 
tumor volume and relevant land marks. Figure 1 shows the central slice from the treatment 
plan, with iso-dose contours at the 10, 30, 50, 70, 80, 90, and 95% levels. Also seen are 
the thermoplastic mask and a cross-section of the frame to which it was fastened. A wax 
bolus is represented on the left posterior of the patient. A three-field technique was used, 
with bilateral and posterior fields using a 6-cm diameter circular field. A 4-cm spread-out 
Figure 1. The central slice from the CT-based proton treatment plan. The inner-most 
outline is the tumor volume. Surrounding outlines represent levels of constant dose at the 
95, 90, 80, 70, 50, 30, and 10% (of the maximum) level. Also visible are the thermoplastic 
mask and mounting frame, and the wax bolus used at the left posterior. 
Bragg peak (SOBP) was achieved with a range modulator, and a different range shifter 
was installed for each field treated. Figure 2 shows a single field dose distribution measured 
in a water phantom as a function of depth and lateral position. Prior to each treatment, 
the position of the tumor relative to the beam center was verified by an x-ray port film. 
Adjustment of the patient was performed until the desired position of the target region 
was achieved. Field placement accuracy was within 2 mm. 
Four months post-treatment, a PET scan of the patient's brain was performed and 
compared to a pre-treatment PET scan. The comparison revealed the disappearance of 
FDG (Flouro 18-Deoxy-Glucose) uptake, which indicates tumor response to treatment. 
There were no acute complications observed, and no signs of radionecrosis. The patient is 
being carefully followed for delayed toxicity. 
With the combined photon and proton therapy, we are hoping to gain superior tumor 
control for this patient, and hopefully obtain longer survival duration. With successful 
delivery of precision proton beam irradiation, we hope to develop proton treatment for 
other primary brain malignancies, prost ate cancer, cholangiocarcinoma, locally advanced 
head and neck carcinoma, and rectal tumors. 
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Figure 2. A single field dose distribution as measured in a water phantom. The origin on 
the depth axis represents the maximum depth of the Bragg peak, while the origin on the 
lateral axis represents the beam's central axis. 
Most recently, the United States Food and Drug Administration granted the IU proton 
therapy facility an investigational device exemption, allowing further treatments of this 
type. Preparations are presently in progress for the next patients. 
Support for the creation of this proton radiation therapy center was provided by 
Indiana University, and the Lions Cancer Control Fund of Indiana, Inc. Special thanks 
are also due to the entire staff at IUCF for their cooperation and assistance over the past 
three years. 
